Screening and selection of peptides specific for esophageal cancer cells from a phage display peptide library

Journal of Cardiothoracic Surgery

You-Bin Cui³  Shi-Yun Feng³  Wei Wang³  Yong-Xin Wang¹  Xue Shan²  Zhe-Feng Zhang³ 

[1] Department of Gynaecology and Obstetrics, The First Hospital of Jilin University, Changchun, China;Department of Cardiac Surgery, The First Hospital of Jilin University, Changchun, China;Department of Thoracic Surgery, The First Hospital of Jilin University, 71 Xinmin Street, 130021 Changchun, China

关键词: Targeted cancer therapy;    Subtractive screening;    Esophageal cancer cells;    Phage display;   

Others  :  810475
DOI  :  10.1186/1749-8090-9-76

 received in 2013-12-03, accepted in 2014-04-24,  发布年份 2014

【 摘 要 】

Background

Esophageal cancer is a common malignant tumor of the gastrointestinal tract and is typically diagnosed at an advanced stage due to the absence of early clinical symptoms. Although surgery, chemotherapy, and radiotherapy represent the major treatment methods employed for this cancer, the prognosis of esophageal cancer remains poor.

Methods

A Ph.D.-12^TM Phage Display Peptide Library was screened using an esophageal cancer cell line, Eca109, and a normal esophageal epithelial cell line to identify novel ligands that selectively bind the surface of esophageal cancer cells with high affinity.

Results

Two polypeptides were isolated that exhibited higher binding affinities and specificity for the Eca109 cells. These peptides were further validated using enzyme-linked immunosorbent assays (ELISAs), immunofluorescence assays, and immunohistochemistry assays.

Conclusion

Two polypeptides with high binding affinities to esophageal cancer cells were isolated from the Ph.D.-12^TM Phage Display Peptide Library. Further studies are needed to characterize the biological effects of these polypeptides and to explore the potential for these peptides to be used for the early screening of esophageal cancer or for cell-targeted therapies that would reduce the toxic side effects of cancer treatment.

【 授权许可】

   
2014 Zhang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Ilson DH: Esophageal cancer chemotherapy: recent advances. Gastrointest Cancer Res 2008, 2(2):85-92.
• [2]Mukherjee K, Chakravarthy AB, Goff LW, EI-Rifai W: Esophageal adenocarcinoma: treatment modalities in the era of targeted therapy. Dig Dis Sci 2011, 55(12):3304-3314.
• [3]Juergens RA, Forastiere A: Combined modality therapy of esophageal cancer. J NatlComprCancNetw 2008, 6(9):851-860. quiz 861
• [4]Lu H, Zheng YF, Jin DD: Application of laser capture microdissection in screening phage-display peptide library from osteosarcoma tissues. Di Yi Jun Yi Da Xue Xue Bao 2002, 22(12):1079-1080.
• [5]Hamzeh-Mivehroud M, Mahmoudpour A, Dastmalchi S: Identification of new peptide ligands for epidermal growth factor receptor using phage display and computationally modeling their mode of binding. Chem Biol Drug Des 2012, 79(3):246-259.
• [6]Liang S, Lin T, Ding J, Pan Y, Dang D, Guo C, Zhi M, Zhao P, Sun L, Hong L, Shi Y, Yao L, Liu J, Wu K, Fan D: Screening and identification of vascular-endothelial-cell-specific binding peptide in gastric cancer. J Mol Med (Berl) 2006, 84(9):764-773.
• [7]Wang FY, Zhang TY, Luo JX, He GA, Gu QL, Xiao F: Selection of CC chemokine receptor 5-binding peptide from a phage display peptide library. Biosci Biotechnol Biochem 2006, 70(9):2035-2041.
• [8]Zhang B, Zhang Y, Wang J, Zhang Y, Chen J, Pan L, Hu Z, Zhao J, Liao M, Wang S: Screening and identification of a targeting peptide to hepatocarcinoma from a phage display peptide library. Mol Med 2007, 13(5–6):246-254.
• [9]Rivinoja A, Laakkonen P: Identification of homing peptides using the in vivo phage display technology. Methods MolBiol 2006, 683:401-415.
• [10]Arap W, Pasqualini R, Ruoslahti E: Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998, 279(5349):377-380.
• [11]Popkov M, Rader C, Barbas CF: Isolation of human prostate cancer cell reactive antibodies using phage display technology. J Immunol Methods 2004, 291(1–2):137-151.
• [12]Mier W, Kramer S, Zitzmann S, Altmann A, Leotta K, Schierbaum U, Schnolzer M, Eisenhut M, Haberkorn U: PEGylation enables the specific tumor accumulation of a peptide identified by phage display. Org Biomol Chem 2013, 11(16):2706-2711.
• [13]Wang W, Chen X, Li T, Li Y, Wang R, He D, Luo W, Li X, Wu X: Screening a phage display library for a novel FGF8b-binding peptide with anti-tumor effect on prostate cancer. Exp Cell Res 2013, 319(8):1156-1164.
• [14]Pande J, Szewczyk MM, Grover AK: Pha ge display: concept, innovations, applications and future. Biotechnol Adv 2010, 28(6):849-858.
• [15]Barry MA, Dower WJ, Johnston SA: Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries. Nat Med 1996, 2(3):299-305.
• [16]Ruan W, Sassoon A, An F, Simko JP, Liu B: Identification of clinically significant tumor antigens by selecting phage antibody library on tumor cells in situ using laser capture microdissection. Mol Cell Proteomics 2006, 5(12):2364-2373.
• [17]Smith GP: Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985, 228(4705):1315-1317.
• [18]Hall PR, Hjelle B, Njus H, Ye C, Bondu-Hawkins V, Brown DC, Kilpatrick KA, Larson RS: Phage display selection of cyclic peptides that inhibit Andes virus infection. J Virol 2009, 83(17):8965-8969.
• [19]Sadanandam A, Varney ML, Kinarsky L, Ali H, Mosley RL, Singh RK: Identification of functional cell adhesion molecules with a potential role in metastasis by a combination of in vivo phage display and in silicoanalysis. OMICS 2007, 11(1):41-57.
• [20]Davis ID, Liu Z, Saunders W, Lee FT, Spirkoska V, Hopkins W, Smyth FE, Chong G, Papenfuss AT, Chappell B, Poon A, Saunder TH, Hoffman EW, Old LJ, Scott AM: A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma. Cancer Immun 2007, 7:14.
• [21]Langer M, Beck-Sickinger AG: Peptides as carrier for tumor diagnosis and treatment. Curr Med Chem Anticancer Agents 2001, 1(1):71-93.
• [22]Xu C, Lo A, Yammanuru A, Tallarico AS, Brady K, Murakami A, Barteneva N, Zhu Q, Marasco WA: Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology. PLoS ONE 2010, 5(3):e9625.